Trial · NCT03187301
Results by group188
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 188
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 15 mins post-dose | 0.2 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 15 mins post-dose | -3.7 | Standard Error 1.97 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 30 mins post-dose | 0.3 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 30 mins post-dose | -2.7 | Standard Error 1.97 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 45 mins post-dose | 0.0 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 45 mins post-dose | -3.7 | Standard Error 1.97 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 60 mins post-dose | 2.7 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 60 mins post-dose | -3.5 | Standard Error 1.97 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 2 hours post-dose | 1.8 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 2 hours post-dose | -3.0 | Standard Error 1.97 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 3 hours post-dose | 0.1 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 3 hours post-dose | -1.6 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | APL-130277 (Cross-over) | 4 hours post-dose | -0.9 | Standard Error 1.98 | msec |
Time-Matched Change From Baseline in QTc, Placebo-Adjusted and Corrected for Heart Rate Based on the Fridericia Correction Method (QTcF) Using Delta Delta Method (ΔΔQTcF): Comparison Between APL-130277 and Placebo (Central Tendency Analysis) | Placebo (Cross-over) | 4 hours post-dose | -0.2 | Standard Error 1.98 | msec |
| Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277 | 10 mg APL-130277 PK Subset | Apomorphine | 5.14 | Standard Deviation 3.28 | ng/mL |
| Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277 | 15mg AP:-130277 PK Subset | Apomorphine | 6.57 | Standard Deviation 1.22 | ng/mL |
| Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277 | 20 mg AP:-130277 PK Subset | Apomorphine | 4.23 | Standard Deviation 2.81 | ng/mL |
| Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277 | 25 mg APL-130277 PK Subset | Apomorphine | 4.16 | Standard Deviation 2.54 | ng/mL |
| Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277 | 35 mg APL-130277 PK Subset | Apomorphine | 9.29 | Standard Deviation 9.97 | ng/mL |
| Cmax of Apomorphine and Apomorphine Sulfate (Metabolite) Following the Administration of APL-130277 | 50 mg AP:-130277 PK Subset | Apomorphine | 4.61 | Standard Deviation NA | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03187301/results